Leadership
Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercialization
Meet our leadership teamLatest news
View more news >Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Rare perspective
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare disease
Read our blog >